Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers
Cancer cells are characterized by a higher rate of protein turnover and greater demand for protein homeostasis compared to normal cells. In this scenario, the ubiquitin–proteasome system (UPS), which is responsible for the degradation of over 80% of cellular proteins within mammalian cells, becomes...
Main Authors: | Xiaonan Zhang, Stig Linder, Martina Bazzaro |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/4/902 |
Similar Items
-
Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention
by: Chee Wai Fhu, et al.
Published: (2021-03-01) -
Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy
by: Fatemeh Aliabadi, et al.
Published: (2021-04-01) -
Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
by: Gabriel LaPlante, et al.
Published: (2021-06-01) -
Targeting the MYC Ubiquitination-Proteasome Degradation Pathway for Cancer Therapy
by: Xiao-Xin Sun, et al.
Published: (2021-06-01) -
The poxvirus ubiquitin ligase p28 manipulates the ubiquitin proteasome system
by: Mottet, Kelly
Published: (2010)